Dacuronium bromide
(Redirected from 17β-hydroxypancuronium)
 | |
| Clinical data | |
|---|---|
| Other names | NB-68; 17β-Hydroxypancuronium bromide; 3α-(Acetyloxy)-17β-hydroxy-2β,16β-bis(1-methylpiperidinium-1-yl)-5α-androstane dibromide; 2β,16β-Dipiperidino-5α-androstane-3α,17β-diol 3α-acetate dimethobromide |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.043.834 |
| Chemical and physical data | |
| Formula | C33H58Br2N2O3 |
| Molar mass | 690.646 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Dacuronium bromide (INN, BAN) (developmental code name NB-68) is an aminosteroid neuromuscular blocking agent which was never marketed.[1][2][3][4][5] It acts as a competitive antagonist of the nicotinic acetylcholine receptor (nAChR).[2]
References
[edit]- ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 647–. ISBN 978-1-4757-2085-3.
- ^ a b Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 90–. ISBN 978-94-011-4439-1.
- ^ Progress in Medicinal Chemistry. Elsevier. 1 January 1979. pp. 102–. ISBN 978-0-08-086264-4.
- ^ Maclagan J (1976). "Competitive neuromuscular blocking drugs.". Neuromuscular Junction. Berlin, Heidelberg: Springer. pp. 421–486. ISBN 978-3-642-45476-9.
- ^ Kharkevich DA (6 December 2012). New Neuromuscular Blocking Agents: Basic and Applied Aspects. Springer Science & Business Media. pp. 201–202, 213. ISBN 978-3-642-70682-0.
 | This article about a steroid is a stub. You can help Wikipedia by expanding it. |
 | This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |